BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34855243)

  • 1. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
    Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
    Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
    Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
    Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy for advanced cutaneous squamous cell carcinoma.
    Fitzgerald K; Tsai KK
    Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
    Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
    Ascierto PA; Schadendorf D
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
    Wessely A; Steeb T; Leiter U; Garbe C; Berking C; Heppt MV
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.
    Boutros A; Cecchi F; Tanda ET; Croce E; Gili R; Arecco L; Spagnolo F; Queirolo P
    Front Oncol; 2021; 11():733917. PubMed ID: 34513710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
    In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
    Giri A; Bauman JR
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
    Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients.
    Hock BD; McIntosh ND; McKenzie JL; Pearson JF; Simcock JW; MacPherson SA
    Intern Med J; 2016 Dec; 46(12):1414-1421. PubMed ID: 27664975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature.
    Corneli P; Conforti C; Retrosi C; Vezzoni R; di Meo N; Piccolo V; Farinazzo E; Russo T; Magaton Rizzi G; Giuffrida R; Zalaudek I
    Dermatol Ther; 2020 Mar; 33(2):e13250. PubMed ID: 32022968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical treatment of advanced cutaneous squamous-cell carcinoma.
    Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
    Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.
    Lang R; Welponer T; Richtig E; Wolf I; Hoeller C; Hafner C; Nguyen VA; Kofler J; Barta M; Koelblinger P; Hitzl W; Emberger M; Laimer M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1799-1810. PubMed ID: 37210651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.